Last week a number of companies working in the transcatheter aortic valve implantation/replacement (TAVI/TAVR) space presented data at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. While the big hitters in the space shared the bulk of the TAVI spotlight at TCT, namely Medtronic (Minneapolis) and Edwards Lifesciences (Irvine, California), there was also well-deserved enthusiasm for some of the smaller players, like Direct Flow Medical (Santa Rosa, California).